News | Radiation Therapy | March 25, 2021

Northern Sydney Cancer Centre Partners with Sun Nuclear as Newest SunCHECK Platform Reference Site

Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK Quality Management Platform.

March 25, 2021 — Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK Quality Management Platform. The center joins leading clinics worldwide already in the reference site program. Globally, SunCHECK technology is used by more than 1,000 users in nearly 60 countries – for integrated, automated and independent quality assurance in radiation therapy.

In partnering with Sun Nuclear, the NSCC will support development of best practices for clinical use, advise on ongoing platform development, and serve as a regional resource for a rapidly-growing community of SunCHECK users. The NSCC is an integrated cancer care network, provided by the Northern Sydney Local Health District (NSLHD). As a public facility with university affiliations, the NSCC is actively involved in cancer research and dedicated to improving outcomes for patients and their families. The center treats more than 1,400 patients annually, using three Varian Medical Systems® linear accelerators and a robust auto-planning program. The NSCC also uses an Elekta brachytherapy system.

Jeremy Booth, Head of Medical Physics for the NSCC, stated that the center is a pioneer in advanced treatments, initiating its IMRT program in 2001 and its SBRT program in 2007. Today, the NSCC remains focused on continually investigating the feasibility of technological changes, including motion management.   

"As a busy clinic with an active research program, we need an efficient, proven quality assurance mechanism," said Booth. "SunCHECK provides the comprehensive functionality and departmental integration we were looking for and offers the efficiency our workload demands."  

The SunCHECK Platform automates and integrates quality management, enabling radiation therapy departments to standardize patient and machine quality assurance (QA) workflows among staff, machines, and locations. A secure, browser-based network architecture connects multiple systems and can support different geographic locations, offering a top-down view through a single dashboard, supported by a single database.

SunCHECK Patient software incorporates Plan Checks, Secondary Calculations, Pre-Treatment QA and In-Vivo Monitoring all in a single workflow. SunCHECK™ Machine software integrates all Machine QA needs, including daily, monthly, and annual QA; automated imaging, MLC and VMAT QA; and data trending. Plus, device integration with the Daily QA 3, IC PROFILER and ArcCHECK arrays enables further automation and centralization of data.

Additional SunCHECK Platform reference sites include: St. George's Cancer Care Centre (Christchurch, New Zealand), Sterling Hospitals Group (Ahmadabad, India), Iridium Kankernetwerk (Antwerp, Belgium), Sant Pau (Barcelona, Spain), ONCORAD (Toulouse, France), The Clatterbridge Cancer Centre (Liverpool, UK), I.R.C.C.S di Candiolo (Candiolo, Italy), UF Health Cancer Center at Orlando Health (Florida, U.S.), and Mosaic Life Care (Missouri, U.S.).

For more information:

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
At the recent 2021 AAPM Meeting in July, Sun Nuclear Corporation featured its comprehensive portfolio of independent, integrated quality management solutions for radiation therapy and diagnostic imaging.
News | Quality Assurance (QA) | September 02, 2021
September 2, 2021 — At the recent 2021 AAPM Meeting
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.